December 29, 2005 -- Alkermes and Cephalon received an approvable letter for their alcohol dependence drug, now called Vivitrol, a long acting formulation of a generic drug that blunts an alcoholic high; Novartis won FDA approval of an add-on indication for Femara, its breast cancer drug; Quidel can now claim its 10-minute flu test is 94% accurate including for avian flu; Bristol-Myers Squibb completed its application for approval of a leukemia drug; Genta applied for FDA approval of Genasense as an adjuvant leukemia treatment; and Arena Pharma will move its cardiovascular drug from the lab into the clinic next year. The Centient Biotech 200™ was 19 points lower at 3958.64, a loss of .47%. More details...
